NGeneBio's diagnostic products start to be used in clinical tests in Vietnam

South Korea's medical diagnostics company NGeneBio Co. said on Wednesday that it is expanding its business in the Southeast Asian precision diagnostics market.

The Kosdaq-listed firm is a next-generation sequencing (NGS) precision diagnosis platform company. NGeneBio's breast and ovarian cancer precision diagnosis products began to be used for clinical tests at Ho Chi Minh City's national and public hospitals. The Vietnam National Cancer Institute is also planning to start clinical trials using the devices.

NGeneBio's precision diagnosis products, which have been highly praised in the local clinical field, can detect genetic mutations in hereditary breast and ovarian cancer patients, and help in early diagnosis for them.

"We are also discussing the possible adoption of NGeneBio products in Vietnam's largest national and public hospitals in Hanoi," said an NGeneBio official.

Once clinical tests begin in earnest in Vietnam, it will become easier to supply products to state-run hospitals through public bidding for medical devices and expand the adoption in private medical centers.

"We plan to nimbly respond to local regulations and customer needs by providing advanced genome analysis services, and focus on new clinical trials and biddings to preempt the Southeast Asian market," said Choi Dae-chul, CEO of NGeneBio.

Write to Ji-Hyun Lee at bluesky@hankyung.com